BEGIN:VCALENDAR
VERSION:2.0
PRODID:-// - ECPv4.7.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.mdtechcouncil.com/membership/events
X-WR-CALDESC:Events for 
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231023T080000
DTEND;TZID=America/New_York:20231027T170000
DTSTAMP:20260430T212401
CREATED:20231025T133009Z
LAST-MODIFIED:20231025T133009Z
UID:4062-1698048000-1698426000@www.mdtechcouncil.com
SUMMARY:2023 Economic Development Week in Maryland
DESCRIPTION:Overview\nEconomic Development Week in Maryland will emphasize the importance of economic development for the State of Maryland. The week is designed to increase understanding of economic development’s contribution to the state’s business climate\, job retention and growth\, the tax base\, and the overall quality of life in Maryland. \nRecognition\nEconomic development will take center stage in counties\, cities\, and towns throughout Maryland when proclamations are made heralding the significant projects that have made Maryland a great place to live\, work\, and play. Recognizing the dedicated work of economic developers is a primary focus of the effort. \n
URL:https://www.mdtechcouncil.com/membership/events/calendar/2023-economic-development-week-in-maryland/
CATEGORIES:Life Science,Manufacturing,Other,Technology
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231025T080000
DTEND;TZID=America/New_York:20231025T140000
DTSTAMP:20260430T212401
CREATED:20231025T133019Z
LAST-MODIFIED:20231025T133019Z
UID:4063-1698220800-1698242400@www.mdtechcouncil.com
SUMMARY:2023 MEDA Fall Conference
DESCRIPTION:The 2023 MEDA Fall Conference will be held October 25\, 2023 at the Antrim 1844 in Carroll County\, MD and the theme will be Innovations in Manufacturing. \nTo receive a 20% discount on your room reservation for the 2023 MEDA Fall Conference\, use the GROUP CODE ‘2310MEDAAT’ when booking on the Antrim 1844 website\, select your stay dates as October 24-25\, 2023\, and be sure to choose the group code option\, not the promotional code. \n
URL:https://www.mdtechcouncil.com/membership/events/calendar/2023-meda-fall-conference/
LOCATION:Antrim 1844\, 30 Trevanion Road\, Taneytown\, MD\, 21787
GEO:39.6548568;-77.1730297
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Antrim 1844 30 Trevanion Road Taneytown MD 21787;X-APPLE-RADIUS=500;X-TITLE=30 Trevanion Road:geo:-77.1730297,39.6548568
CATEGORIES:Manufacturing
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231025T090000
DTEND;TZID=America/New_York:20231025T130000
DTSTAMP:20260430T212401
CREATED:20230921T154309Z
LAST-MODIFIED:20230921T154309Z
UID:4010-1698224400-1698238800@www.mdtechcouncil.com
SUMMARY:Harnessing the Potential of Antibody Drug Conjugates in Oncology
DESCRIPTION:Join us for Harnessing the Potential of Antibody Drug Conjugates (ADCs) in Oncology\, on October 25 at Johnson & Johnson Innovation – JLABS @ Washington\, DC. We’ll host industry thought leaders  as they dig deeper on how ADCs have become a promising cancer treatment and key component in the next generation of oncology therapeutics. \nDubbed ‘the next pillar of cancer therapeutics’\, ADC technology delivers highly potent treatment agents to specific tumor cells connected to malignancy. From 2019 – 2022\, 8 ADCs received FDA approval and dozens more investigational treatments flooded the industry pipeline. Our program will explore the resurgence around their potential in oncology\, showcasing innovation in ADC development\, exploring the current science and regulatory landscape for oncology\, and highlighting investors’ perspectives as breakthrough research that requires support pours in. \nAfter the programming concludes\, there will be an opportunity to participate in partnering meetings to connect one-on-one with industry leaders in this space.  All individuals (startups\, oncology companies\, academics and researchers\, industry partners) interested in being considered for an opportunity for one-on-one partnering will need to apply by Friday\, October 6th. Selected companies will be notified of their acceptance on Wednesday\, October 18th. \n
URL:https://www.mdtechcouncil.com/membership/events/calendar/harnessing-the-potential-of-antibody-drug-conjugates-in-oncology/
LOCATION:Johnson & Johnson Innovation – JLABS @ Washington\, DC\, 7144 13th Pl NW\, Suite 2200\, Washington\, DC\, 20012\, United States
GEO:38.976951;-77.0325182
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Johnson & Johnson Innovation – JLABS @ Washington DC 7144 13th Pl NW Suite 2200 Washington DC 20012 United States;X-APPLE-RADIUS=500;X-TITLE=7144 13th Pl NW\, Suite 2200:geo:-77.0325182,38.976951
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231025T110000
DTEND;TZID=America/New_York:20231025T120000
DTSTAMP:20260430T212401
CREATED:20231025T133038Z
LAST-MODIFIED:20231025T133038Z
UID:4071-1698231600-1698235200@www.mdtechcouncil.com
SUMMARY:NCI Technology Opportunity Webinar: Anti-EGFR Antibodies for the Treatment of Human Cancers
DESCRIPTION:Register to attend a free NIH webinar. Attendees will learn about new antibodies developed in Dr. David Fitzgerald’s Lab that bind a particular structure on the external domain of epidermal growth factor receptor (EGFR) which is displayed on cancer cells that express high EGFR levels or the variant termed ‘EGFRvIII’. Importantly\, these antibodies do not bind normal cells. Therefore\, these antibodies are used to deliver toxic payloads (as antibody-drug conjugates – ADCs) to cancer cells without killing normal cells. Additionally\, these antibodies are superior to currently approved drugs that target this receptor\, including ligand-blocking monoclonal antibodies and small molecular weight kinase inhibitors. Further\, this presentation will show that tumors expressing high levels of human EGFR experience a significant reduction in size after treatment with several distinct ADCs made in Dr. Fitzgerald’s Lab. \nWebinar overview: The presentation will follow a logical sequence of how anti-EGFR antibodies are generated and modified to make them cytotoxic for tumor cells with high levels of EGFR or the variant EGFRvIII; specifically focusing on beginning with a key mouse monoclonal antibody termed ‘40H3’ and then transitioning to the humanization of this antibody to produce the antibody termed ‘A10’. These anti-EGFR antibodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs)\, antibody-drug conjugates (ADCs)\, bispecific antibodies\, and chimeric antigen receptors (CARs). \n
URL:https://www.mdtechcouncil.com/membership/events/calendar/nci-technology-opportunity-webinar-anti-egfr-antibodies-for-the-treatment-of-human-cancers/
LOCATION:Virtual Event
CATEGORIES:Life Science
END:VEVENT
END:VCALENDAR